Anticoagulation in Peripheral Artery Disease: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 04.04.2026 · 1 (1)
DOI: 10.62487/saimsaraac354ec8 ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 04.04.2026. Die Arbeit nennt 70 Literaturangaben.
Abstract (Originalsprache)
The aim of this paper is to synthesize current evidence regarding the efficacy, safety, and clinical implementation of anticoagulation in patients with PAD, evaluating the impact of different regimens on limb patency, cardiovascular mortality, and bleeding complications across various clinical settings. The review utilises 110 original studies with 2351292 total participants (topic deduplicated ΣN). The evidence map identifies low-dose rivaroxaban plus aspirin as the most consistent anticoagulation-related signal in PAD, with reported reductions of 24% in MACE and 43% to 47% in MALE, alongside a major bleeding increase with hazard ratios around 1.70 to 1.78. This pattern was most persuasive in symptomatic and post-revascularization PAD, where intensified therapy also appeared to reduce total thrombotic events and venous thromboembolism, supporting a practical role for dual pathway inhibition in carefully selected patients. At the same time, the broader evidence base indicates that full-dose or nonspecific anticoagulation strategies do not uniformly translate across PAD contexts, particularly after some endovascular procedures or in younger revascularized cohorts, where harm signals and treatment heterogeneity remain important concerns. In PAD patients with concomitant atrial fibrillation, the mapped literature also supports maintaining indicated oral anticoagulation and suggests DOAC-based strategies may be preferable to warfarin for overall vascular outcomes. Overall, the review supports a selective, risk-stratified approach that balances limb and cardiovascular protection against bleeding risk rather than a uniform escalation of anticoagulation in all PAD patients. Future research should prioritize indication-specific randomized and prospective comparative studies to define optimal regimens for post-intervention PAD, PAD-VTE overlap, and AF-PAD populations, while improving bleeding-risk stratification and real-world implementation.
Zitieren
APA
(2026). Anticoagulation in Peripheral Artery Disease: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsaraac354ec8
Vancouver
Anticoagulation in Peripheral Artery Disease: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsaraac354ec8
BibTeX
@article{euvimed2026,
title = {Anticoagulation in Peripheral Artery Disease: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsaraac354ec8}
}
EUVIMED